Melane Sampson, Author at BioTuesdays

Developments

Altamira Therapeutics provides business update

Altamira Therapeutics (NASDAQ:CYTO) provided a business update as it repositions around RNA therapeutics and continues to progress towards upcoming key catalysts with its non-RNA legacy programs. “We are...

April 12, 2022

Developments

Viz.ai raises $100-million in Series D round

Closely held Viz.ai raised $100-million to expand its artificial-intelligence platform designed to detect and triage strokes, heart attacks and aneurysms by scanning patient imagery. The Series D funding round led by...

April 6, 2022

Developments

Australian committee approves Claritas Phase 1 trial of R-107

The Australian Human Research Ethics Committee has approved Claritas Pharmaceuticals’ (TSXV:CLAS; OTC:CLAZF) submission for the Phase 1 clinical study of R-107 to be conducted at Scientia Clinical Research in Sydney...

April 5, 2022

Markets

Analysts downgrade Silverback; two oncology programs discontinued

Analysts for H.C. Wainwright and SVB Leerink downgraded Silverback Therapeutics (NASDAQ:SBTX) after the company discontinued two leading oncology programs. The stock closed at $3.21 on April 1. The company discontinued...

April 1, 2022

Markets

Cantor cuts Akebia to neutral from OW; PT to $1 from $6

Cantor Fitzgerald downgraded Akebia Therapeutics (NASDAQ:AKBA) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company received a complete response letter in response to the NDA for...

March 31, 2022

Executive Moves

Sigyn Therapeutics names neurology leader Dr. Ajay Verma to SAB

Ajay Verma Sigyn Therapeutics (OTC:SIGY) appointed Ajay Verma, M.D., Ph.D., a recognized thought leader in the field of neurology, to its scientific advisory board. Dr. Verma’s extensive clinical experience and insights...

March 31, 2022

Executive Moves

Long-time research analyst Anthony Petrone joins Mizuho Americas

Anthony Petrone Mizuho Americas hired Anthony Petrone as a managing director, senior medical devices, diagnostics and therapeutics equity research analyst. Mr. Petrone has more than 16 years of experience in...

March 28, 2022

Developments

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Palisade Bio (NASDAQ:PALI) received a “study may proceed” letter from the FDA for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing...

March 22, 2022

Developments

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Closely held Cytovale announced that a new study of its investigational IntelliSep test has been published in the peer-reviewed journal, PLOS ONE. The study demonstrated that the IntelliSep test has the potential to...

March 17, 2022

Developments

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Immunomic Therapeutics plans to start a Phase 1 clinical study of a plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer, using PharmaJet’s...

March 15, 2022

Author - Melane Sampson

Altamira Therapeutics provides business update

Viz.ai raises $100-million in Series D round

Australian committee approves Claritas Phase 1 trial of R-107

Analysts downgrade Silverback; two oncology programs discontinued

Cantor cuts Akebia to neutral from OW; PT to $1 from $6

Sigyn Therapeutics names neurology leader Dr. Ajay Verma to SAB

Long-time research analyst Anthony Petrone joins Mizuho Americas

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Subscribe